Neurocrine Biosciences, Inc. (0K6R)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 142.97 |
|---|---|
| 52-week range | 118.72 – 190.00 |
| Return, 1 month / 3 months | +0.2% / −18.2% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -25.7% |
| Average daily value traded | 0.24M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California, that discovers and develops medicines for neurological, psychiatric and endocrine disorders. Its products include treatments for movement disorders such as tardive dyskinesia and for hormone-related conditions such as endometriosis, along with therapies for other central nervous system conditions. The company serves patients and healthcare providers, and it also runs research programmes aimed at new treatments for nervous system and hormonal diseases.
Neurocrine Biosciences, Inc. trades under the code 0K6R on the London Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Neurocrine Biosciences, Inc. (0K6R) trades on the London Exchange in UK. It last closed at USD 142.97 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,242 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 44 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.0% | ||
| From 52-week high | -21.4% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.2% | ||
| 6-month return | 9.2% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.7% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.24M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | +0.2% |
| 3 months | −18.2% |
| 6 months | +9.2% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 147.76 / 147.35 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 5.09 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.